Julie M. Vose
Expertise in
34
conditions

Dr. Julie M. Vose

Hematology | Oncology
505 S 45th St., 
Omaha, NE 
Offers Telehealth
42 Years of Experience
Expertise in
34
conditions
505 S 45th St., 
Omaha, NE 

Overview

Julie Vose is a Hematologist and an Oncologist practicing medicine in Omaha, Nebraska. She has been practicing medicine for over 42 years.

Dr. Vose is highly rated in 34 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 257 peer reviewed articles and participating in 16 clinical trials.

Graduate Institution

UNMC College Of Medicine, 1984

Residency

UNMC College of Medicine, Internal Medicine

Specialties

Hematology
Oncology

Licenses

Internal Medicine in NE

Fellowships

UNMC College of Medicine, Hematology/Oncology - 1990

Hospital Affiliations

Bellevue Medical Center
The Nebraska Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 9 Less Insurance Carriers -

Locations

Fred & Pamela Buffett Cancer Center - Nebraska Medical Center
505 S 45th St., Omaha, NE 68105
Other Locations
Fred & Pamela Buffett Cancer Center - Village Pointe Health Center
111 N. 175th St., Omaha, NE 68118

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Biological
Study Drug: MEDI-570
Study Phase: Phase 1
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Enrollment Status: Completed
Publish Date: April 08, 2026
Intervention Type: Drug
Study Drugs: Tisagenlecleucel, Platinum-based immunochemotherapy, high dose chemotherapy
Study Phase: Phase 3
A Pilot Study of Vitamin D Replacement in Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia With Low Vitamin D Levels
A Pilot Study of Vitamin D Replacement in Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia With Low Vitamin D Levels
Enrollment Status: Completed
Publish Date: March 31, 2026
Intervention Type: Dietary supplement, Other
Study Drug: Cholecalciferol
Study Phase: Not Applicable
Investigator Initiated Pilot Study of Microarray Directed Therapy for Diffuse Large B-cell Lymphoma Using Genasense With CHOP-R
Investigator Initiated Pilot Study of Microarray Directed Therapy for Diffuse Large B-cell Lymphoma Using Genasense With CHOP-R
Enrollment Status: Terminated
Publish Date: October 24, 2023
Intervention Type: Genetic, Drug, Biological, Procedure, Other
Study Phase: Early Phase 1
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin?s Lymphoma
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin?s Lymphoma
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Biological, Drug, Procedure
Study Phase: Phase 1/Phase 2
A Phase 2 Multicenter, Investigator Initiated Study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-Cell and Peripheral T-Cell Non-Hodgkin Lymphoma
A Phase 2 Multicenter, Investigator Initiated Study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-Cell and Peripheral T-Cell Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: October 05, 2023
Intervention Type: Drug, Other
Study Drug: Ruxolitinib Phosphate
Study Phase: Phase 2
A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma
A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: September 22, 2023
Intervention Type: Drug, Genetic, Other
Study Phase: Phase 2
Phase I Study of Carfilzomib for the Treatment of T-Cell Lymphoma
Phase I Study of Carfilzomib for the Treatment of T-Cell Lymphoma
Enrollment Status: Completed
Publish Date: September 15, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/II Trial of Rituxan and BEAM High-Dose Chemotherapy and Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma
A Phase I/II Trial of Rituxan and BEAM High-Dose Chemotherapy and Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma
Enrollment Status: Completed
Publish Date: September 07, 2023
Intervention Type: Drug, Procedure
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

257 Total Publications

Proteome landscape of B-cell malignancies identifies mantle cell lymphoma protein signature.
Proteome landscape of B-cell malignancies identifies mantle cell lymphoma protein signature.
Journal: bioRxiv : the preprint server for biology
Published: March 23, 2026
Similar Doctors
Expertise in
24
conditions
Dr. Vijaya R. Bhatt
Hematology | Oncology
Expertise in
24
conditions
Dr. Vijaya R. Bhatt
Hematology | Oncology

Fred & Pamela Buffett Cancer Center - Nebraska Medical Center

505 S 45th St., 
Omaha, NE 
 (0.2 miles away)
402-559-5600
Experience:
18+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Vijaya Bhatt is a Hematologist and an Oncologist practicing medicine in Omaha, Nebraska. He has been practicing medicine for over 18 years. Dr. Bhatt is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
21
conditions
Dr. James O. Armitage
Hematology | Oncology
Expertise in
21
conditions
Dr. James O. Armitage
Hematology | Oncology

Fred & Pamela Buffett Cancer Center - Nebraska Medical Center

505 S 45th St., 
Omaha, NE 
 (0.2 miles away)
402-559-5600
Experience:
53+ years
Languages Spoken:
English
See accepted insurances

James Armitage is a Hematologist and an Oncologist practicing medicine in Omaha, Nebraska. He has been practicing medicine for over 53 years. Dr. Armitage is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Endoscopy.

Expertise in
38
conditions
Dr. Matthew A. Lunning
Hematology
Expertise in
38
conditions
Dr. Matthew A. Lunning
Hematology

Fred & Pamela Buffett Cancer Center - Nebraska Medical Center

505 S 45th St., 
Omaha, NE 
 (0.2 miles away)
402-559-5600
Experience:
20+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matthew Lunning is a Hematologist practicing medicine in Omaha, Nebraska. He has been practicing medicine for over 20 years. Dr. Lunning is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, T-Cell Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Julie M. Vose

How do I make an appointment with Dr. Julie M. Vose?

You can book an appointment with Dr. Julie M. Vose by calling their office at 402-559-5600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Julie M. Vose a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Julie M. Vose is classified as an Elite expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Julie M. Vose specialize in?

While Dr. Julie M. Vose is a Hematology, they have specific expertise in Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, and Mantle Cell Lymphoma (MCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Julie M. Vose participate in research or clinical trials?

Yes. Dr. Julie M. Vose has published 257 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Julie M. Vose's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Julie M. Vose accept my insurance?

Dr. Julie M. Vose accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 402-559-5600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vose's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 13 Distinguished Conditions
View All 13 Advanced Conditions
View All 32 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile